Phase I/II Dose-Escalation Study of the Pan-Histone Deacetylase (HDAC) Inhibitor PCI-24781 in Lymphoma.

Trial Profile

Phase I/II Dose-Escalation Study of the Pan-Histone Deacetylase (HDAC) Inhibitor PCI-24781 in Lymphoma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Nov 2016

At a glance

  • Drugs Abexinostat (Primary)
  • Indications Cutaneous T cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; MALT lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pharmacyclics
  • Most Recent Events

    • 19 Oct 2015 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 04 Apr 2014 Primary endpoint added as reported by ClinicalTrials.gov.
    • 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top